As investors and industry observers track the launch of Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), gene-based therapies approved in December 2023 for certain sickle cell disease and beta thalassemia patients, the CEOs of CRISPR Therapeutics AG and bluebird bio are exuding confidence that all will go well commercially.
“I don’t see fundamental roadblocks or fundamental issues as we look at these launches,” Samarth Kulkarni, CEO of CRISPR Therapeutics,...